IL‐38: A novel cytokine in systemic lupus erythematosus pathogenesis

Autor: Jia-Min Wang, Zhen Qin, Xiao-Yan Liu, Xi-Ping Zhou, An-Fang Huang, Zhi-Chao Yuan, Wang-Dong Xu, Lin-Chong Su
Rok vydání: 2020
Předmět:
Adult
Male
0301 basic medicine
IL‐38
medicine.medical_treatment
Interleukin-1beta
Inflammation
medicine.disease_cause
Peripheral blood mononuclear cell
Autoimmunity
Proinflammatory cytokine
Pathogenesis
Mice
03 medical and health sciences
0302 clinical medicine
immune system diseases
medicine
Animals
Humans
Lupus Erythematosus
Systemic
skin and connective tissue diseases
Systemic lupus erythematosus
Proteinuria
Interleukin-6
Tumor Necrosis Factor-alpha
business.industry
Interleukins
autoimmunity
Original Articles
lupus
Cell Biology
Middle Aged
medicine.disease
030104 developmental biology
Cytokine
inflammation
030220 oncology & carcinogenesis
Immunology
Interleukin-23 Subunit p19
Leukocytes
Mononuclear
Cytokines
Molecular Medicine
Original Article
Female
medicine.symptom
business
Interleukin-1
Zdroj: Journal of Cellular and Molecular Medicine
ISSN: 1582-4934
1582-1838
DOI: 10.1111/jcmm.15737
Popis: IL‐38 is a newly identified cytokine that belongs to the IL‐1 family. In our previous study, we found elevated plasma levels of IL‐38 in patients with systemic lupus erythematosus (SLE). However, the clear relationship of IL‐38 expression in plasma, peripheral blood mononuclear cells (PBMCs) and clinical and laboratory features needs elucidation. Additionally, we evaluated the possible role of IL‐38 in regulating production of inflammatory cytokines in PBMCs in vitro. A pristane‐induced murine lupus model was used to further demonstrate the effects of IL‐38 on cytokines in vivo and discuss the significance of IL‐38 in lupus development. The results showed that mRNA expression of IL‐38 in PBMCs of patients with SLE was elevated compared with volunteers, and expression of IL‐38 in both plasma and PBMCs was strongly related to clinical features, such as haematuria and proteinuria, and correlated with a SLEDAI score. Plasma levels of TNF‐α, IL‐1β, IL‐6 and IL‐23 were elevated in patients with SLE and were related to plasma levels of IL‐38. In vitro, PBMCs of patients with SLE stimulated with IL‐38 showed a decreased expression of the four inflammatory cytokines compared with PBMCs of patients without treatment. Interestingly, IL‐38 administration in lupus mice significantly reduced the development of lupus, such as reduced proteinuria, improved histological examinations of the kidneys and down‐regulated inflammatory cytokines. In conclusion, IL‐38 may suppress synthesis of pro‐inflammatory cytokines and therefore regulate lupus pathogenesis.
Databáze: OpenAIRE
Externí odkaz: